Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A candidate DNA vaccine pTHgagC expressing the immunodeficiency virus-1 (HIV-1) gag gene from South African isolate Du422 was constructed and characterised. The isolate was selected on the basis of being the closest to the South African subtype C consensus sequence. Sequence analysis of cytotoxic T lymphocyte (CTL) epitopes showed that HIV subtype C-infected individuals have CTL responses to a number of epitopes present in the vaccine, but also revealed a more limited presence of subtype A- and any B-derived epitopes. A high level of expression of the immunogen was demonstrated in human cells and a potent, long-lived CTL response to a single inoculation of the DNA vaccine was elicited in BALB/c mice, which could be significantly increased by a boost vaccination at 4 weeks. This is the first candidate HIV-1 DNA vaccine employing the South African subtype C sequences, and constitutes a part of a vaccine scheduled to enter a clinical evaluation in South Africa in 2004.

Type

Journal article

Journal

Vaccine

Publication Date

01/10/2003

Volume

21

Pages

4380 - 4389

Keywords

AIDS Vaccines, Amino Acid Sequence, Animals, Chromium Radioisotopes, Cytotoxicity Tests, Immunologic, DNA, Complementary, Genes, gag, HIV-1, HeLa Cells, Humans, Immunization, Interferon-gamma, Mice, Mice, Inbred BALB C, Molecular Sequence Data, South Africa, T-Lymphocytes, Regulatory, Vaccines, DNA